Page 107 - 《中国药房》2021年第1期

42（6）：1147-1154. 21（6）：1-10.
[ 5 ] FISKER F，MØLLER N，LAURITZEN ES. Sodium-glu- [15] GARG SK，HENRY RR，BANKS P，et al. Effects of sota-
cose-cotransporter 2 inhibitor-associated euglycaemic dia- gliflozin added to insulin in patients with type 1 diabe-
betic ketoacidosis[J]. Ugeskr Laeger，2019，181（21）：25- tes[J]. N Engl J Med，2017，377（24）：2337-2348.
33. [16] THOMAS D，BERTRAND C，PHILLIP B，et al. HbA1c
[ 6 ] HERNANDEZ-QUILES C，RAMIREZ-DUQUE N，ACOS- and hypoglycemia reductions at 24 and 52 weeks with so-
TA-DELGADO D. Ketoacidosis due to empagliflozin，a tagliflozin in combination with insulin in adults with type
paradigm shift：case report and review of literature[J]. 1 diabetes：the European intandem2 study[J]. Diabetes
Curr Diabetes Rev，2019，15（4）：259-262. Care，2018，41（9）：1981-1990.
[ 7 ] HIGGINS JP，ALTMAN DG，GØTZSCHE PC，et al. The [17] BUSE JB，GARG SK，JULIO R，et al. Sotagliflozin in
Cochrane Collaboration’s tool for assessing risk of bias in combination with optimized insulin therapy in adults with
randomised trials[J]. BMJ ，2011，343（7829）：889-893. type 1 diabetes：the North American intandem1 study[J].
[ 8 ] HENRY RR，THAKKAR P，TONG C，et al. Efficacy and Diabetes Care，2018，41（9）：1970-1980.
safety of canagliflozin，a sodium glucose cotransporter 2 [18] BAKER C，WASON S，BANKS P，et al. Dose dependent
inhibitor，as add-on to insulin in patients with type 1 diabe- glycometabolic effects of sotagliflozin on type 1 diabetes
tes[J]. Diabetes Care，2015，38（12）：2258-2265. over 12 weeks：the intandem4 trial[J]. Diabetes Obes
[ 9 ] PARESH D，CHANTAL M，MOSHE P，et al. Efficacy and Metab，2019，21（11）：2440-2449.
safety of dapagliflozin in patients with inadequately con- [19] Lexicon Pharmaceuticals. Efficacy and safety of sotagli-
trolled type 1 diabetes：the depict-1 52-week study[J]. Dia- flozin in young adult patients with type 1 diabetes melli-
betes Care，2018，41（12）：2552-2559. tus and elevated hemoglobin A1C[EB/OL].[2020-06-01].
[10] CHANTAL M，PARESH D，PIETER G，et al. Efficacy https：//www.clinicaltrials.gov/ct2/show/NCT02383940?
and safety of dapagliflozin in patients with inadequately term=NCT02383940&draw=2&rank=1.
controlled type 1 diabetes（the depict-2 study）：24-week [20] EL MASRI D，GHOSH S，JABER LA. Safety and effica-
results from a randomized controlled trial[J]. Diabetes cy of sodium-glucose cotransporter 2（SGLT2）inhibitors
Care，2018，41（9）：1938-1946. in type 1 diabetes：a systematic review and meta-analy-
[11] ROSENSTOCK J，MARQUARD J，LAFFEL LM，et al. sis[J]. Diabetes Res Clin Pract，2018. DOI：10.1016/j.dia-
Empagliflozin as adjunctive to insulin therapy in type 1 bres.2018.01.004.
diabetes：the EASE trials[J]. Diabetes Care，2018，41（12）： [21] MUSSO G，GAMBINO R，CASSADER M，et al. Efficacy
2560-2569. and safety of dual SGLT 1/2 inhibitor sotagliflozin in type
[12] Boehringer Ingelheim. Empagliflozin as adjunctive to in- 1 diabetes：meta-analysis of randomised controlled
sulin therapy over 52 weeks in patients with type 1 diabe- rials[J]. BMJ，2019. DOI：10.1136/bmj.l1328.
tes mellitus （EASE-2） [EB/OL].[2020-06-01]. https：// [22] LANGFORD BE，EVANS M，HASKINS-COULTER T，
www.clinicaltrials.gov/ct2/show/NCT02414958?term= et al. Systematic literature review and network meta-analy-
NCT02414958&draw=2&rank=1. sis of SGLT inhibitors versus metformin as add on to insu-
[13] Boehringer Ingelheim. Empagliflozin as adjunctive to in- lin in type 1 diabetes[J]. Diabetes Obes Metab，2019，22
sulin therapy over 26 weeks in patients with T1DM （1）：39-50.
（EASE-3） [EB/OL].[2020-06-01]. https：//www.clinical- [23] YAMADA T，SHOJIMA N，NOMA H，et al. Sodium-glu-
trials.gov/ct2/show/NCT02580591?term=NCT02580591 cose co-transporter 2（SGLT2）inhibitors as add-on thera-
&draw=2&rank=1. py to insulin for type 1 diabetes mellitus：systematic re-
[14] KAKU K，ISAKA H，SAKATANI T，et al. Efficacy and view and meta-analysis of randomized controlled trials[J].
safety of ipragliflozin add-on therapy to insulin in Japa- Diabetes Obes Metab，2018，20（7）：1755-1761.
nese patients with type 1 diabetes mellitus：a randomized， （收稿日期：2020-07-23 修回日期：2020-10-21）
double-blind，phase 3 trial[J]. Diabetes Obes Metab，2019， （编辑：刘明伟）

中国药房 2021年第32卷第1期 China Pharmacy 2021 Vol. 32 No. 1 ·97 ·